Clinical Trials NCT04586010

Active, Not RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
746
Target enrollment
23
U.S. states
Mar 2021
Start date
Nov 2027
Expected completion
Interventions / Treatments
FenebrutinibTeriflunomidePlacebo
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (32 sites)
California3 sites
Carlsbad · Irvine · Pasadena
Colorado3 sites
Aurora · Denver · Fort Collins
Ohio3 sites
Centerville · Columbus · Columbus
Alabama2 sites
Birmingham · Homewood
Louisiana2 sites
Baton Rouge · Shreveport
Texas2 sites
Plano · Sherman
Arizona1 site
Phoenix
Florida1 site
Maitland
Illinois1 site
Highland Park
Indiana1 site
Fort Wayne
Maryland1 site
Baltimore
Worcester
Michigan1 site
Detroit
Missouri1 site
St Louis
Teaneck
Albuquerque
Oklahoma1 site
Oklahoma City
Bethlehem
Greenville
Tennessee1 site
Knoxville
Virginia1 site
Vienna
Kirkland
Wisconsin1 site
Milwaukee
MS centers in California

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View California centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play